Acute Myeloid Leukemia PBMC

In Stock Samples

31 samples
Condition
Lot #

Start typing to see matching lot #.

Format
Volume / Size
Gender
Age Range
Race / Ethnicity

Start typing to see matching race / ethnicity.

Medications

Start typing to see matching medications.

Comorbidities

Start typing to see matching comorbidities.

Country of Collection
31 lots available
Acute Myeloid Leukemia (AML) PBMC 78765 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 78766 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 78767 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 78796 Female 61+ Cryopreserved 1.5 mL 1 10M Empagliflozin, Cytarabine, Azacitidine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78797 Female 61+ Cryopreserved 1.5 mL 1 10M Empagliflozin, Cytarabine, Azacitidine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78798 Female 61+ Cryopreserved 1.5 mL 1 10M Empagliflozin, Cytarabine, Azacitidine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78799 Female 61+ Cryopreserved 1.5 mL 1 10M Empagliflozin, Cytarabine, Azacitidine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78800 Female 61+ Cryopreserved 1.5 mL 1 10M Empagliflozin, Cytarabine, Azacitidine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78780 Male 61+ Cryopreserved 1.5 mL 1 10M No medications, Daunorubicin, Cytarabine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78813 Female 61+ Cryopreserved 1.5 mL 1 10M Carvedilol Ukraine
Acute Myeloid Leukemia (AML) PBMC 78814 Female 61+ Cryopreserved 1.5 mL 1 10M Carvedilol Ukraine
Acute Myeloid Leukemia (AML) PBMC 78781 Male 61+ Cryopreserved 1.5 mL 1 10M No medications, Daunorubicin, Cytarabine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78815 Female 61+ Cryopreserved 1.5 mL 1 10M Carvedilol Ukraine
Acute Myeloid Leukemia (AML) PBMC 78782 Male 61+ Cryopreserved 1.5 mL 1 10M No medications, Daunorubicin, Cytarabine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78783 Male 61+ Cryopreserved 1.5 mL 1 10M No medications, Daunorubicin, Cytarabine Ukraine
Acute Myeloid Leukemia (AML) PBMC 78816 Female 61+ Cryopreserved 1.5 mL 1 10M Carvedilol Ukraine
Acute Myeloid Leukemia (AML) PBMC 78761 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 78762 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 78763 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 78764 Female 61+ Cryopreserved 1.5 mL 1 10M Amlodipine, Azacitidine, Venetoclax, Dexamethasone Ukraine
Acute Myeloid Leukemia (AML) PBMC 75968 156197 Female 61+ Hispanic/Latino Cryopreserved 1 mL 5 10M 2026
Acute Myeloid Leukemia (AML) PBMC 75966 156809 Male 61+ Hispanic/Latino Cryopreserved 1 mL 15 10M 2026
Acute Myeloid Leukemia (AML) PBMC 75965 156091 Female 61+ Hispanic/Latino Cryopreserved 1 mL 10 10M 2026
Acute Myeloid Leukemia (AML) PBMC 75964 156462 Female 61+ Hispanic/Latino Cryopreserved 1 mL 5 10M 2026
Acute Myeloid Leukemia (AML) PBMC 76787 Female 61+ Cryopreserved 1 mL 1 10M Rosuvastatin, Valsartan Ukraine

Showing 1–25 of 31 lots

About Acute Myeloid Leukemia PBMC

High-Quality Acute Myeloid Leukemia PBMC for Research

Acute Myeloid Leukemia (AML) PBMC products are sourced from donors clinically diagnosed with acute myeloid leukemia (AML) and processed under stringent conditions to support immune response in oncology research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on immune response and biomarker identification.

Product Features

  • Research Use Only (RUO), cryopreserved AML PBMC Samples
  • Clinically confirmed AML donors
  • Processed within 24 hours of collection
  • Stored using CryoStor® CS10 freezing media
  • IRB-approved protocols and electronic informed consent

De-identified Donor Data

  • Verified AML diagnosis
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported allergies and infectious disease history
  • Additional acute myeloid leukemia (aml)-specific data available upon request

Applications

  • Biomarker discovery and validation
  • Drug screening and therapeutic development
  • Immune pathway analysis in AML pathophysiology
  • Transcriptomic and proteomic profiling

Quality and Compliance

  • IRB-approved collections and protocols
  • 21 CFR Part 11 – compliant e-consent system
  • HIPAA-compliant donor data protection

Ordering & Shipping

Acute Myeloid Leukemia PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.

Donor Metadata

  • Verified diagnosis and clinical history
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Medication and treatment background when available

Compliance and Quality Assurance

  • IRB-approved collections and standardized procedures
  • 21 CFR Part 11-compliant e-consent system
  • HIPAA-compliant data management

Ordering & Customization

Human PBMC are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Where can I find your complete catalog?
How long can samples be stored?

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

What customization options are available?

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Do you offer prospective collections?

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

What is the turnaround time for custom collections?

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

Do you have samples in stock?

YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

What does unique donor mean?

Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

Are samples collected under IRB-approved protocols?

YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

Frequently Asked Questions

×

Ask a Question

Pair with a Healthy Control

Match your Acute Myeloid Leukemia PBMC with normal donor samples for comparison

Healthy PBMC

806 In Stock
Screened normal donors · Cryopreserved · Starting at $205
View Inventory

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information